```html

Kernicterus – What You Need to Know

What is Kernicterus?

Kernicterus, also called bilirubin-induced neurological dysfunction (BIND), is a rare but severe form of brain injury that occurs when very high levels of unconjugated bilirubin cross the blood‑brain barrier and deposit in the basal ganglia, brainstem, and cerebellum. The condition most often affects newborn infants, especially those with premature birth or hemolytic disease, but it can also appear later in life in patients with liver failure or untreated severe jaundice.

Unconjugated bilirubin is a yellow pigment produced when red blood cells break down. Normally, the liver converts it into a water‑soluble form that can be eliminated in stool. When the conversion process is overwhelmed or the bilirubin cannot be cleared, the pigment builds up in the bloodstream (hyperbilirubinemia) and may become toxic to neurons.

According to the Mayo Clinic, the hallmark of kernicterus is permanent neurologic damage that can manifest as movement disorders, hearing loss, visual deficits, and cognitive impairment.

Common Causes

Although kernicterus is most frequently seen in newborns, a variety of underlying conditions can precipitate the dangerous rise in bilirubin levels that leads to brain injury. The most common causes include:

• Hemolytic disease of the newborn (HDN) – Rh or ABO incompatibility leading to rapid red‑cell destruction.
• Premature birth – Immature liver enzymes (UDP‑glucuronosyltransferase) cannot conjugate bilirubin efficiently.
• Breast‑feeding jaundice – Inadequate milk intake in the first few days reduces stool output and bilirubin excretion.
• Breast‑milk jaundice – Certain substances in breast milk inhibit bilirubin conjugation after the first week of life.
• Genetic enzyme deficiencies – e.g., Crigler‑Najjar syndrome type I & II, Gilbert syndrome (mild) and Rotor syndrome.
• Blood group incompatibilities other than Rh – e.g., Kell, Duffy, or other minor antigens.
• Sepsis or severe infections – Increase hemolysis and impair liver function.
• Major trauma or surgery – Massive blood loss leads to increased bilirubin production.
• Liver disease – Biliary atresia, neonatal hepatitis, or metabolic disorders (e.g., galactosemia) reduce bilirubin clearance.
• Medications that displace bilirubin from albumin – Certain antibiotics (e.g., sulfonamides) and anesthetics can increase free bilirubin.

Associated Symptoms

Early signs of severe hyperbilirubinemia may be subtle, but as bilirubin crosses into the central nervous system, a characteristic constellation of neurologic and systemic symptoms appears.

• Yellowing of the skin and sclera (jaundice) that does not improve after 48–72 hours of life.
• Lethargy, poor feeding, or difficulty waking for feeds.
• High‑pitched crying or irritability that is out of proportion to typical newborn fussiness.
• Hypotonia (floppy limbs) progressing to hypertonia (spasticity) especially in the arms and legs.
• Abnormal eye movements (nystagmus) or inability to track objects.
• Auditory dysfunction – newborns may not respond to sounds, later leading to sensorineural hearing loss.
• Seizure activity – focal or generalized tonic‑clonic seizures.
• Movement disorders later in life – athetoid (writhing) movements, dystonia, or cerebral palsy‑like features.
• Developmental delay, intellectual disability, and visual impairment (cortical blindness).

When to See a Doctor

Newborn jaundice is common and often benign, but certain red flags demand urgent medical evaluation:

• Jaundice that spreads to the chest, abdomen, or limbs within the first 24 hours of life.
• Skin that looks deep yellow or orange, especially on the palms and soles.
• Newborn who is unusually sleepy, difficult to wake, or has a weak suck.
• Vomiting, especially if it contains blood.
• Any seizure‑like activity, stiffening, or abnormal movements.
• Signs of dehydration – dry mouth, no wet diapers for >6 hours.
• Family history of bilirubin‑processing disorders or previous child with severe jaundice.

If any of these occur, seek pediatric care immediately; early intervention can prevent irreversible brain injury.

Diagnosis

Because kernicterus is a diagnosis of both clinical suspicion and laboratory confirmation, physicians use a stepwise approach:

1. Physical Examination

• Assessment of jaundice distribution and intensity (using a transillumination device or visual scoring).
• Neurologic exam for tone, reflexes, eye movements, and responsiveness.

2. Laboratory Tests

• Serum total bilirubin (TSB) – measured in mg/dL; levels >20 mg/dL in term infants or >15 mg/dL in preterm infants are high‑risk thresholds (American Academy of Pediatrics guidelines).
• Direct (conjugated) vs. indirect (unconjugated) bilirubin – kernicterus is linked to markedly elevated indirect bilirubin.
• Complete blood count and reticulocyte count – assess hemolysis.
• Blood type and Coombs test – detect maternal‑infant incompatibility.
• Liver function panel – rule out hepatic causes.

3. Imaging & Specialized Tests

• Transcranial ultrasound or MRI – May reveal basal ganglia signal changes in established kernicterus.
• Auditory brainstem response (ABR) testing – Evaluates early hearing loss.
• Eye examination – Checks for pigment deposition and optic nerve involvement.
• Genetic testing when hereditary enzyme deficiencies are suspected.

4. Scoring Systems

The CDC/AAP exchange transfusion nomogram and the Bhutani nomogram help clinicians decide when phototherapy or exchange transfusion is indicated based on bilirubin level, age in hours, and risk factors.

Treatment Options

Management aims to rapidly reduce serum bilirubin and prevent further neuronal damage. Treatment is tiered based on severity.

1. Phototherapy

• First‑line therapy for most cases of significant neonatal jaundice.
• Blue‑green light (460–490 nm) converts unconjugated bilirubin into water‑soluble isomers that are excreted without conjugation.
• Intensity: intensive (≥30 µW/cm²/nm) for high‑risk infants; medium for moderate risk.
• Duration is guided by serial bilirubin levels, typically 12–48 hours.

2. Exchange Transfusion

• Reserved for bilirubin levels that exceed exchange‑transfusion thresholds (e.g., >25 mg/dL in term infants) or when rapid neurologic decline is evident.
• Procedure replaces the infant’s blood with donor blood, halving the bilirubin load.
• Requires specialist neonatal intensive care unit (NICU) support and meticulous monitoring for complications (electrolyte imbalance, infection, hemolysis).

3. Intravenous Immunoglobulin (IVIG)

• Used when hemolytic disease of the newborn is caused by maternal antibodies.
• IVIG blocks Fc receptors and reduces further hemolysis, lowering bilirubin production.

4. Medications

• Phenobarbital – Can induce hepatic UDP‑glucuronosyltransferase activity in certain congenital deficiencies; however, its use is limited due to side effects.
• Experimental agents (e.g., heme‑oxygenase inhibitors) are under investigation but not standard care.

5. Supportive Care

• Ensuring adequate hydration and caloric intake – frequent feeds or IV fluids.
• Monitoring for electrolyte disturbances, especially calcium and phosphate.
• Neurodevelopmental follow‑up with physiotherapy, occupational therapy, and audiology if kernicterus develops.

Prevention Tips

Because the condition is largely preventable, most pediatric guidelines focus on early detection and prompt treatment of jaundice.

• Universal bilirubin screening – Measure TSB or transcutaneous bilirubin within 24 hours of birth and again at 48–72 hours, especially for preterm infants.
• Encourage early, frequent feeding – Breastfed babies should nurse at least 8–12 times per day to promote stool output and bilirubin excretion.
• Educate parents – Teach how to recognize worsening jaundice (yellowing of abdomen, palms, soles) and signs of poor feeding.
• Avoid drugs that displace bilirubin – Discuss medication safety with healthcare providers, especially sulfonamides and certain anesthetics.
• Prompt treatment of hemolytic disease – Antenatal identification of Rh incompatibility and administration of Rh immunoglobulin (Rho(D) immune globulin) to Rh‑negative mothers.
• Manage underlying liver disease – Early referral for biliary atresia or metabolic disorders.
• Consider home phototherapy units – For low‑risk infants with moderate jaundice, physician‑prescribed home devices can reduce hospital readmissions.

Emergency Warning Signs

Key Take‑aways

• Kernicterus is a preventable brain injury caused by extremely high unconjugated bilirubin.
• Prematurity, hemolytic disease, and inadequate feeding are the most common precipitants.
• Watch for persistent or worsening jaundice, poor feeding, lethargy, and abnormal movements.
• Rapid bilirubin reduction using phototherapy, exchange transfusion, or IVIG can stop the disease in its tracks.
• Regular newborn bilirubin screening and early, frequent feeding are the cornerstone of prevention.

For more detailed information, consult reputable sources such as the Mayo Clinic, CDC, and the National Institute of Child Health and Human Development (NICHD).

```